MELANOMA Neoadjuvant administration of the oncolytic virus T-VEC improved OS in advanced melanoma.

Web

Dec. 9, 2019

SCIENTIFIC

MELANOMA: Neoadjuvant administration of the oncolytic virus T-VEC improved OS in advanced melanoma.

 

Presented at the 16th International Congress of the Society for Melanoma Research; November 20-23, 2019; Salt Lake City, UT.

 

Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma (MEL): 3-year landmark analysis of a randomized phase 2 trial

Jason Chesney et al;

 

Improved recurrence-free survival (RFS) from a randomized phase 2 study of neoadjuvant (neo) talimogene laherparepvec (T-VEC) plus surgery (surg) vs surg for resectable stage IIIB-IVM1a melanoma (MEL)

Reinhard Dummer et al

 

Abstracts Here